The global deuterated drugs market, valued at US$ 334.0 million in 2023, presents a robust growth pattern. With a projected valuation of US$ 871.8 million by 2032 at a CAGR of 11.25%, the market is ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

Traders and investors observed major market averages edge lower Monday, the final trading session of September, but large-cap ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Italian Prime Minister Giorgia Meloni met the head of the U.S. fund BlackRock Inc , Larry Fink, in Rome on Monday to discuss ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites ...

Dr Joseph Berger reviews findings showing how newer drugs like satralizumab, eculizumab, and inebilizumab outperformed older neuromyelitis optica spectrum disorder treatments.

The epigenetic drugs space has witnessed a two-fold increase in Series A venture funding, with total deal value increasing to ...

Savara says it will in the first of half next year seek an FDA license to treat autoimmune pulmonary alveolar proteinosis ...